Clinical and Technical Considerations for Brain PET Imaging for Dementia

被引：5

作者：

Acuff, Shelley N. ^{[1
]}

Mathotaarachchi, Sulantha ^{[2
]}

Zukotynski, Katherine ^{[3
,4
,5
]}

Osborne, Dustin ^{[1
]}

Subramaniam, Rathan ^{[5
]}

机构：

[1] Univ Tennessee, Grad Sch Med, Dept Radiol, Med Ctr, Knoxville, TN 37920 USA

[2] McGill Univ, Res Ctr Studies Aging, Montreal, PQ, Canada

[3] McMaster Univ, Dept Med, Hamilton, ON, Canada

[4] McMaster Univ, Dept Radiol, Hamilton, ON, Canada

[5] Univ Texas Southwestern Med Ctr Dallas, Harold Simmons Comprehens Canc Ctr, Dept Radiol, Div Nucl Med, Dallas, TX 75390 USA

来源：

JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | 2020年 / 48卷 / 01期

基金：

美国国家卫生研究院; 加拿大健康研究院;

关键词：

brain; PET; amyloid; tau; TAU; DIAGNOSIS;

D O I：

10.2967/jnmt.118.220087

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The number of cases of dementia has dramatically increased over the last decade. Imaging of the brain with PET has been used for many years, but in the past decade the radiopharmaceuticals and technology available for imaging dementia have vastly improved. In recent years, the U.S. Food and Drug Administration has approved 3 PET radiopharmaceuticals for detecting amyloid in brain, and tau PET radiopharmaceuticals are being investigated in clinical trials for use in dementia imaging. This paper will discuss different forms of dementia that can be imaged with PET, review common radiopharmaceuticals used for imaging dementia, and provide technical recommendations for performing the studies.

引用

页码：5 / 8

页数：4

共 10 条

[1] ACCUMULATION OF ABNORMALLY PHOSPHORYLATED-TAU PRECEDES THE FORMATION OF NEUROFIBRILLARY TANGLES IN ALZHEIMERS-DISEASE [J].

BANCHER, C ;

BRUNNER, C ;

LASSMANN, H ;

BUDKA, H ;

JELLINGER, K ;

WICHE, G ;

SEITELBERGER, F ;

GRUNDKEIQBAL, I ;

IQBAL, K ;

WISNIEWSKI, HM .

BRAIN RESEARCH, 1989, 477 (1-2) :90-99

[2] NEUROPATHOLOGICAL STAGING OF ALZHEIMER-RELATED CHANGES [J].

BRAAK, H ;

BRAAK, E .

ACTA NEUROPATHOLOGICA, 1991, 82 (04) :239-259

[3] Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer's Disease (vol 99, pg 925, 2018) [J].

Eftekharzadeh, Bahareh ;

Daigle, J. Gavin ;

Kapinos, Larisa E. ;

Coyne, Alyssa ;

Schiantarelli, Julia ;

Carlomagno, Yari ;

Cook, Casey ;

Miller, Sean J. ;

Dujardin, Simon ;

Amaral, Ana S. ;

Grima, Jonathan C. ;

Bennett, Rachel E. ;

Tepper, Katharina ;

DeTure, Michael ;

Vanderburg, Charles R. ;

Corjuc, Bianca T. ;

DeVos, Sarah L. ;

Gonzalez, Jose Antonio ;

Chew, Jeannie ;

Vidensky, Svetlana ;

Gage, Fred H. ;

Mertens, Jerome ;

Troncoso, Juan ;

Mandelkow, Eckhard ;

Salvatella, Xavier ;

Lim, Roderick Y. H. ;

Petrucelli, Leonard ;

Wegmann, Susanne ;

Rothstein, Jeffrey D. ;

Hyman, Bradley T. .

NEURON, 2019, 101 (02) :349-349

[4] New Developments in the Diagnosis of Dementia [J].

Eschweiler, Gerhard W. ;

Leyhe, Thomas ;

Kloeppel, Stefan ;

Huell, Michael .

DEUTSCHES ARZTEBLATT INTERNATIONAL, 2010, 107 (39) :677-U22

[5]

Jeong Y, 2005, J NUCL MED, V46, P233

[6]

Johnson KA, 2013, ALZHEIMERS DEMENT, V9, pE1, DOI [10.1016/j.jalz.2013.01.002, 10.1016/j.jalz.2012.10.007, 10.1016/j.jalz.2013.06.001]

[7] Brain PET in the Diagnosis of Alzheimer's Disease [J].

Marcus, Charles ;

Mena, Esther ;

Subramaniam, Rathan M. .

CLINICAL NUCLEAR MEDICINE, 2014, 39 (10) :E413-E426

[8] The history of cerebral PET scanning From physiology to cutting-edge technology [J].

Portnow, Leah H. ;

Vaillancourt, David E. ;

Okun, Michael S. .

NEUROLOGY, 2013, 80 (10) :952-956

[9] Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions [J].

Villemagne, Victor L. ;

Dore, Vincent ;

Burnham, Samantha C. ;

Masters, Colin L. ;

Rowe, Christopher C. .

NATURE REVIEWS NEUROLOGY, 2018, 14 (04) :225-236

[10] Aβ-amyloid and Tau Imaging in Dementia [J].

Villemagne, Victor L. ;

Dore, Vincent ;

Bourgeat, Pierrick ;

Burnham, Samantha C. ;

Laws, Simon ;

Salvado, Olivier ;

Masters, Colin L. ;

Rowe, Christopher C. .

SEMINARS IN NUCLEAR MEDICINE, 2017, 47 (01) :75-88

← 1 →